International Biotechnology Trust – Beating the odds
Strategic positioning in mid-2018 helped International Biotechnology Trust (IBT) beat its benchmark over the past six months and close its discount to NAV. This continued its outperformance of the US Nasdaq Biotechnology Index (NBI) over three and five years. Active management of the portfolio and an increased focus on larger mid-caps played out well in terms of IBT’s performance versus its peers.
IBT’s manager is maintaining its established policy of active risk mitigation, designed to avoid exposure to binary events (typically Phase III readouts) that can cause large swings in the share price. This should be seen as another attraction to investors in the trust. IBT has recently moved to a premium and has been issuing stock.
Access to the fast-growing biotech sector
IBT is the longest-established of the London-listed funds specialising in the biotech/healthcare sector. It aims to achieve long-term capital growth by investing in biotechnology and other life sciences companies, and offers investors the highest yield in the sector while keeping its day-to-day running costs low. The portfolio is invested primarily in quoted companies, but IBT also has some exposure to unquoted companies.
|wdt_ID||Year ended||Share price TR (%)||NAV total return (%)||NASDAQ Biotech Index TR (%)||MSCI UK total return (%)||MSCI World TR (%)|
IBT: International Biotechnology Trust – Beating the odds